Vise Technologies Inc. Purchases 1,359 Shares of Elevance Health, Inc. $ELV

Vise Technologies Inc. grew its position in Elevance Health, Inc. (NYSE:ELV) by 20.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,088 shares of the company’s stock after purchasing an additional 1,359 shares during the quarter. Vise Technologies Inc.’s holdings in Elevance Health were worth $2,835,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ELV. Norges Bank acquired a new stake in shares of Elevance Health in the fourth quarter worth $1,058,165,000. Bank of New York Mellon Corp grew its stake in shares of Elevance Health by 79.3% in the fourth quarter. Bank of New York Mellon Corp now owns 2,408,704 shares of the company’s stock worth $844,371,000 after acquiring an additional 1,065,065 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after acquiring an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC grew its stake in shares of Elevance Health by 25.0% in the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after acquiring an additional 798,457 shares during the last quarter. Finally, Brave Warrior Advisors LLC grew its stake in shares of Elevance Health by 65.3% in the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after acquiring an additional 724,349 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 1.6%

Shares of NYSE:ELV opened at $415.88 on Friday. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $416.56. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The company’s fifty day moving average is $354.74 and its 200-day moving average is $341.76. The company has a market capitalization of $90.31 billion, a PE ratio of 17.69, a P/E/G ratio of 2.35 and a beta of 0.67.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter in the previous year, the company earned $11.97 EPS. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts predict that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ELV shares. Morgan Stanley raised their price objective on shares of Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research note on Thursday. Guggenheim raised their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Truist Financial raised their price objective on shares of Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Robert W. Baird raised their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Finally, UBS Group raised their price objective on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and an average target price of $411.11.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.